Alectinib for advanced ALK -positive non-small-cell lung cancer

American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Ashley C LyMorgan B Smith

Abstract

The pharmacology, pharmacokinetics, clinical efficacy, safety and tolerability, dosage and administration, and place in therapy of alectinib for treatment of patients with non-small-cell lung cancer (NSCLC) are reviewed. In patients with NSCLC driven by mutations of ALK, the gene coding for anaplastic lymphoma kinase (ALK), treatment with the ALK inhibitor crizotinib has been found to provide median progression-free survival (PFS) of 10.9 months; however, therapeutic failures and tumor progression to brain metastases are common with crizotinib use, prompting research to find more potent and tolerable ALK inhibitors that target major oncogenic drivers of NSCLC. Alectinib is a next-generation ALK inhibitor initially approved by the Food and Drug Administration for use in patients with metastatic ALK-positive NSCLC who are intolerant of or have disease progression during crizotinib therapy. In clinical trials, alectinib was found effective for delaying disease progression and, more importantly, reducing brain metastases in patients with NSCLC who developed resistance or intolerance to previous crizotinib therapy. Published data from clinical trials indicate that the most common grade 1 and 2 adverse effects associated with alectin...Continue Reading

References

Aug 12, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alice T ShawA John Iafrate
Feb 15, 2011·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Ruud WiggenraadHenk Struikmans
Jan 12, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert C DoebeleD Ross Camidge
Jan 27, 2012·Science Translational Medicine·Ryohei KatayamaJeffrey A Engelman
Oct 23, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniel S ChenF Stephen Hodi
Mar 29, 2014·Cancer Discovery·Luc FribouletJeffrey A Engelman
Sep 1, 2014·Nature Medicine·Christine M LovlyWilliam Pao
Sep 11, 2014·Cancer Chemotherapy and Pharmacology·Tatsushi KodamaHiroshi Sakamoto
Sep 18, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ryohei KatayamaAlice T Shaw
Oct 29, 2014·British Journal of Cancer·A D'InceccoF Cappuzzo
Dec 4, 2014·The New England Journal of Medicine·Benjamin J SolomonUNKNOWN PROFILE 1014 Investigators
Jan 17, 2015·Journal of Translational Medicine·Mei JiChang-Ping Wu
May 15, 2015·Proceedings of the Japan Academy. Series B, Physical and Biological Sciences·Hiroyuki Mano
May 29, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Keiichi OtaIsamu Okamoto
Nov 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sai-Hong Ignatius OuDong-Wan Kim
Jan 12, 2016·Therapeutic Advances in Medical Oncology·Ivana Sullivan, David Planchard
Aug 9, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Kentaro ItoNobuyuki Yamamoto
Aug 23, 2016·Clinical Pharmacology in Drug Development·Peter N MorcosAlex Phipps
Aug 23, 2016·Clinical Pharmacology in Drug Development·Peter N MorcosAlex Phipps
Nov 20, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Zabi Wardak, Hak Choy
Nov 20, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shirish M GadgeelSai-Hong Ignatius Ou
Jan 5, 2017·Cold Spring Harbor Molecular Case Studies·Vijaykumar R HollaGeorge R Simon
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Feb 19, 2017·Current Problems in Cancer·Rajiv KumarTimothy A Yap
Feb 28, 2017·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Eiji IwamaIsamu Okamoto
Jun 7, 2017·The New England Journal of Medicine·Solange PetersUNKNOWN ALEX Trial Investigators
Jul 15, 2018·Journal of the National Comprehensive Cancer Network : JNCCN·Al B BensonDeborah A Freedman-Cass
Oct 17, 2018·Journal of the National Comprehensive Cancer Network : JNCCN·Crystal S DenlingerDeborah A Freedman-Cass

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Katie Croegaert, Jill M Kolesar
American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Andrew Timm, Jill M Kolesar
American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Jeff A Engle, Jill M Kolesar
© 2022 Meta ULC. All rights reserved